It is understandable that concerns might be raised about the safety of COVID-19 vaccines, particularly as they have been developed with such speed. It is important that the public are able to ask questions. It is, however, even more important that the answers given are balanced and backed by science. 

The UK's Medicines and Healthcare products Regulatory Agency, having conducted a review of the AstraZeneca vaccine following suspensions by some countries of the vaccine over suspected blood clots, have reassuringly advised that the benefits of the vaccine in preventing COVID-19 far outweigh the risks. Their position was echoed by the European Medicines Agency, who added that the vaccine is not associated with an increase in the overall risk of blood clots.

With AstraZeneca reporting that the number of cases of blood clots is lower than the hundreds of cases that would be expected among the general population, could their vaccine even reduce the risk of blood clotting events?